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Peptides with molecular weights below 3 kDa from the hydrolysis of olive seed proteins 31 
with Thermolysin (OS-3kDa), have demonstrated a high antihypertensive capacity. This 32 
fraction has been further fractionated by semipreparative RP-HPLC to obtain 8 33 
fractions. ACE inhibitor capacity of fractions was evaluated observing the highest 34 
capacity in fraction F5. Peptides in fraction F5 were identified by RP-HPLC- and 35 
HILIC-ESI-Q-ToF and cytotoxic effect was assessed in different cell lines. Peptide 36 
LLPSY, present in this faction, was synthesized and characterized. Despite 37 
antihypertensive capacity was not as high as in fraction F5, a significant anti-38 
proliferative capacity on two different cancer cell lines was observed. Additional studies 39 
to assess antitumor activity confirmed that this peptide showed capability to increase the 40 
adhesion capacity of tumor cells, to decrease the migration capacity of cancer cells, and 41 
to arrest cell cycle on S phase. 42 
 43 




































































1. INTRODUCTION 45 
 46 
Olea europaea L. is an evergreen tree found throughout the world but mainly farmed in 47 
Mediterranean countries (Terral et al., 2004; Cavalheiro et al., 2015). Olive processing 48 
generates millions of tons of waste that constitute an environmental problem due to their 49 
high amount of organic and phytotoxic compounds (Bhatnagar et al., 2014). Different 50 
strategies have been developed for the revalorization of these olive by-products 51 
(Roselló-Soto et al., 2015). Olive stones have been used for fuel production, especially 52 
in thermal processes or even to obtain biosorbents for the removal of metal pollutants 53 
(Sánchez, & San Miguel, 2016; Moubarika, & Grimib, 2015). Additionally, other 54 
studies have demonstrated that olive stones contain high-added valuable compounds 55 
such as lipids, polyphenols, free sugars, carotenoids, vitamin E, and proteins (Roselló-56 
Soto et al., 2015, Nunes, Pimentel, Costa, Alves, & Oliveira, 2016). Moreover, olive 57 
seeds have a high protein content and the hydrolysis of these proteins has enabled to 58 
obtain peptides with antioxidant, antihypertensive, and hypocholesterolemic properties 59 
(Esteve, Marina, & García, 2015). 60 
Peptide bioactivity mainly depends on its amino acid composition, sequence, structure, 61 
and other factors such as hydrophobicity, charge or even the binding properties of 62 
peptides (Korhonen & Pihlanto, 2003, Beaulieu, Thibodeau, Bonnet, Bryl & Carboneau, 63 
2013). Antihypertensive peptides mainly act by the inactivation of angiotensin 64 
converting enzyme (ACE), strongly influenced by the C-terminal amino acid sequence 65 
of peptides (Erdmann, Cheung, & Schröder, 2008). ACE is a metalloprotease, zinc 66 
dependent enzyme that catalyzes the hydrolysis of the decapeptide angiotensin I, by 67 




































































responsible for the increase in blood pressure, and also, for the inactivation of 69 
antihypertensive vasodilator bradykinin (Erdmann et al., 2008, Bernstein et al., 2013). 70 
A person is considered hypertensive when the high blood pressure is maintained for 71 
long time and, consequently, hypertension is a risk factor of cardiovascular diseases. 72 
Despite there are synthetic drugs for the treatment of hypertension, there is a growing 73 
interest for finding alternative treatments from natural sources preventing high blood 74 
pressure without exerting side effects (Erdmann et al., 2008, Puchalska, Marina, & 75 
García, 2015). Several research works have shown the potential of ACE inhibitor 76 
peptides from marine organisms (Pangestuti, & Kim, 2017; Wilson, Hayes, & Carney, 77 
2011), animal sources (Mane, & Jamdar, 2017), plant sources, and by-products 78 
(Rizzello et al., 2016). Concretely, ACE-inhibitory peptides have been identified in the 79 
fraction containing peptides with molecular weights (MW) below 3 kDa from the olive 80 
seed proteins hydrolysate (Esteve et al., 2015). 81 
On the other hand, antitumor peptides from natural sources have been extensively 82 
studied. It has been reported that anti-proliferative food peptides could prevent different 83 
stages of cancer, including initiation, promotion, and progression (Gonzalez de Mejia, 84 
& Dia, 2010). Among their mechanisms of action is the inhibition of cell migration, 85 
anti-angiogenesis, and anti-proliferation, which lead to apoptosis and cytotoxic effects 86 
on cancerous cell lines (Bhutia, & Maiti, 2008). Some anti-proliferative peptides from 87 
food proteins are lectins from plants, lunasin from soybean, different peptides from 88 
hazelnuts, amaranth, milk, and egg, and widely studied peptides from marine organisms 89 
(Hernández-Ledesma, & Hsieh, 2017).  90 
The aim of this work has been to further study the fraction containing peptides with 91 




































































antihypertensive capacity. For that purpose, peptides in OS-3kDa will be further 93 
fractionated and fractions will be characterized by the evaluation of its ACE-inhibitory 94 
capacity, the identification of peptides (by HILIC- and RP-HPLC-ESI-Q-ToF and de 95 
novo sequencing), and the study of cytotoxicity. Most interesting peptides will be 96 




































































2. MATERIAL AND METHODS 98 
2.1. Materials 99 
All reagents were of analytical grade. Water was daily obtained with a Milli-Q system 100 
from Millipore (Bedford, MA, USA). Tris(hydroxymethyl) aminomethane (Tris), 101 
hydrochloric acid, sodium phosphate, and sodium dodecyl sulphate (SDS) were from 102 
Merck (Darmstadt, German). Acetic acid (AA), N-(2-hydroxyethyl)-1-piperazinyl-N’-103 
(2-ethanesulfonic) acid (HEPES), tripeptide hippuryl-histidyl-leucine (HHL), 104 
trifluorocetic acid (TFA), angiotensin converting enzyme (ACE) from rabbit lung, 105 
Thermolysin, pancreatic and pepsin enzymes, dimethylsulphoxide (DMSO) 106 
concentrated type-I collagen solution,  propidium iodure (PI), ribonuclease A from 107 
bovine pancreas (RNase A), Bovine serum albumin (BSA), phosphate-buffered saline 108 
(PBS), trypsin, 3-(4,5-dimethyl-2-thiazolyl)-2,5 diphenyltetrazolium bromide (MTT), 109 
and DMEM (Dubelcco’s Modified Eagle's medium) and RPMI-1640 (Roswell Park 110 
Memorial Institute) media were purchased in Sigma-Aldrich (Saint Louis, MO, USA). 111 
Acetonitrile HPLC- and MS-grade (ACN), acetone, and n-hexane were from Scharlau 112 
Chemie (Barcelona, Spain). Peptide LLPSY was synthesized by GenScript Corp. 113 
(Piscataway, NJ, USA) with a purity > 95 %.  Raw olives of Picual variety were 114 
collected in Toledo (Spain).  115 
2.2. Cell lines 116 
Cell lines (human cervical cancer cells (HeLa), human renal proximal tubule epithelial 117 
cells (HK-2), androgen-independent prostate cancer cells (PC-3), and triple-negative 118 
breast cancer cells (MDA-MB-468)) were from the American Type Culture Collection 119 
ATCC (Rockwell, HD, USA). 120 




































































Protein extraction was carried out following a method reported by Esteve et al. (2015). 122 
Briefly, olive seeds were manually pitted, ground, and defatted with n-hexane. Next, 123 
dried and defatted seeds were extracted with a 100 mM Tris-HCl buffer (pH 7.5) 124 
containing 0.5 % (w/v) SDS and DTT using a high intensity focused ultrasound probe 125 
(from Sonic Vibra Cell, CVX 130, Hartford, CT, USA) for 5 min at 30% amplitude. 126 
The mixture was centrifuged for 10 min at 4000 g and proteins were precipitated with 127 
cold acetone for 24 h at - 4 °C. Afterwards, acetone was removed and dried protein 128 
isolated was enzymatically digested in a phosphate buffer (pH 8.0) with Thermolysin at 129 
0.5 g enzyme/ g protein ratio. The blend was incubated in a Thermomixer Compact 130 
(Eppendorf, Hamburg, Germany) keeping the temperature at 50 ºC. After 2 h digestion, 131 
the temperature was increased up to 100 °C for 10 min to stop the digestion. 132 
Hydrolysates were centrifuged at 4500g for 5 min and the supernatant was collected and 133 
fractionated by ultrafiltration using MW cut-off filters of 3 kDa from Merck Millipore 134 
(Tullagreen, Ireland).  135 
 136 
2.4. Fractionation by semipreparative reversed-phase high performance liquid 137 
chromatography (RP-HPLC) 138 
An HPLC system equipped with a quaternary pump (1100 Series, Agilent Technologies, 139 
Waldbron, Germany), an injection system, and a variable wavelength detector (both 140 
1265 Series, Agilent Technologies) was employed. A Jupiter 4 µm Proteo 90 Å 141 
chromatographic column (250 mm x 10 mm) from Phenomenex (Torrance, CA, USA) 142 
was employed. Chromatographic conditions were: mobile phases, 0.1% (v/v) TFA in 143 
water (phase A) and in ACN (phase B); elution gradient, 15-20% B in 5 min, 20-25% B 144 
in 15 min, and 25-40% B in 15 min. Furthermore, the flow rate was 1 mL/min, the 145 




































































wavelengths were set at 254, 280 nm and, moreover fluorescence detection at excitation 147 
wavelength 280 nm and emission 360 nm.  Eight fractions, collected every 5 min from 148 
minute 10, were obtained. Samples were injected 4 times and evaporated using a 149 
centrifugal evaporator (Concentrator Plus, Eppendorf, Hamburg, Germany). The 150 
remaining solid was dissolved in 2400 μL of digestion buffer. Fractions were kept at - 151 
20 °C until their use.  152 
 153 
2.5. ACE-inhibitory capacity measurements 154 
The ACE-inhibitory capacity was assayed following the method described by Vásquez-155 
Villanueva et al. (Vásquez-Villanueva, Marina, & García, 2015). Shortly, 2.5 µL of 156 
sample was added to a solution containing 17.5 µL of 50 mM HEPES, 5 µL of 1.3 157 
mg/mL HHL (freshly prepared in 50 mM HEPES (pH 8.3) and 300 mM NaCl), and 10 158 
µL of an ACE solution (0.05 U/mL). The blend was incubated for 4 h at 37 °C and ACE 159 
was inactivated by the addition of 50 µL of cold ACN. During reaction, peptide HHL 160 
was converted into hippuric acid (HA) and they were separated by RP-HPLC using a 161 
Zorbax SB-C18 column (0.5 x 150 mm, 5 µm) from Agilent. Chromatographic 162 
conditions were: mobile phases, 0.05% (v/v) TFA in water (phase A) and in ACN 163 
(phase B); elution gradient, 5-95% B in 12 min; flow rate, 20 µL/min; injection volume, 164 
10 µL and temperature, 25 °C. UV detection wavelength was set at 228 nm. Sample 165 
ACE-inhibition was depicted as the percentage of inhibition (Mosmann, 1983). The 166 
concentration required for the 50% inhibition of ACE activity (IC50) was evaluated in 167 
those samples exceeding 50% of ACE-inhibition. For that purpose, the percentage of 168 
ACE-inhibition corresponding to, at least, six sample dilutions was plotted against the 169 
sample concentration and IC50 was obtained by interpolation at 50 % of ACE activity. 170 




































































2.6 Identification of ACE-inhibitory peptides by HILIC- and RP-HPLC-ESI-Q-ToF  172 
Identification of peptides was carried out using an Agilent HPLC system equipped with 173 
a quaternary pump (1100 Series, Agilent Technologies, Waldbron, Germany), an 174 
injection system, and a variable wavelength detector (both 1265 Series, Agilent 175 
Technologies). This system was coupled to a Quadrupole-Time-of-Flight (Q-ToF) mass 176 
spectrometer (Series 6350), also from Agilent. Peptide separation was carried out by 177 
RP-HPLC and by hydrophilic interaction liquid chromatography (HILIC). An Ascentis 178 
Express Peptide ES-C18 column (100 mm x 2.1 mm I.D., 2.7 µm particle size) and an 179 
Ascentis Express HILIC column (100 mm x 2.1 mm I.D., 2.7 µm particle size), both, 180 
with their corresponding guard columns (5 mm x 2.1 mm, 2.7 µm particle size) from 181 
Supelco (Bellefonte, PA, USA), were employed. RP-HPLC chromatographic conditions 182 
were: mobile phases, 0.3 % (v/v) AA in water (phase A) and in ACN (phase B); elution 183 
gradient: 3% B for 3 min and 3-25 % in 30 min. Chromatographic conditions for the 184 
HILIC separation were: mobile phases, 65 mM ammonium acetate in ACN (phase A) 185 
and 65 mM ammonium acetate in water (phase B); elution gradient, 5-20% B in 20 min 186 
and 20-30% B in 15 min. Other common chromatographic conditions were: flow rate, 187 
0.3 mL/min; column temperature, 25 °C; injection volume, 10 µL.  188 
Mass spectrometry (MS) detection was carried out in the positive ion mode using a 189 
scanning range from 100 to 1500 m/z. Tandem MS was performed using Auto 190 
(MS/MS) mode and collision induced dissociation was set at 5 V per each 100 Da. De 191 
novo sequencing of peptides was carried out with PEAKS Studio 7 software from 192 
Bioinformatic Solutions Inc. (Waterloo, ON, Canada). Identified peptides showed an 193 
average local confidence (ALC, expected percentage of correct amino acids in the 194 
peptide sequence) equal or superior to 90% and a good precursor fragmentation pattern. 195 




































































2.7. Cytotoxicity assessment by MTT assay 197 
Cytotoxic effect of peptides in fraction F5 and of peptide LLPSY was estimated by cell 198 
metabolic activity measurements. For that purpose, HeLa, HK-2, PC-3, and MDA-MB-199 
468 cells were employed and the colorimetric MTT assay reported by Mosmann et al. 200 
(1983) was followed. Shortly, cells were seeded in a 96-well plate to obtain a cell 201 
density of 1.0  10
4
 viable cells/well. Culture medium was constituted by DEMEM or 202 
RPMI-1640 media containing penicillin-streptomycin and 10 % fetal bovine serum 203 
(FBS). They were kept at 37 °C in a humidified atmosphere with 5 % of CO2 until use. 204 
Peptides were added at increasing concentrations to every cell culture. After 24 h 205 
incubation of cells with peptides, a 5 mg/mL MTT stock solution in PBS was added to 206 
each well in a 1:10 (cell volume: MTT stock solution volume) ratio and incubated for 4 207 
h at 37 °C. Afterwards, MTT solution was carefully removed and formazan crystals, 208 
formed by viable mitochondria, were solubilized with 500 μL DMSO. The absorbance 209 
of formazan crystals was measured at a wavelength of 570 nm (with a reference 210 
wavelength at 630 nm) using automated microplate reader (Model ELX 800, Bio-tek 211 
instruments, INc., Winooski, VT, USA). Cytotoxicity was expressed as the percentage 212 
of viability of cells treated with peptides relative to that the corresponding controls. Cell 213 
viability was calculated as follow:  214 
                   
         
          
      
where,           and            is the absorbance of remaining blue formazan when 215 
cells are treated with sample (F5 fraction or peptide LLPSY) and digestion buffer, 216 





































































2.8. Cell Adhesion assay 219 
A concentrated type-I collagen solution was diluted in 10 mM glacial acetic acid and 220 
coated onto 96-well plates for 1 h at 37 °C. Plates were washed twice with PBS (pH 7.4) 221 
and cells were harvested with 0.25% trypsin/0.2% EDTA and collected by 222 
centrifugation. They were suspended in medium/0.1% (w/v) BSA (pH 7.4) and treated 223 
with 62.91 μg/mL of LLPSY peptide concentration (for PC-3 cells) and 97.56 μg/mL 224 
(for MDA-MB-468 cells) for 80 min. Control sample involved no addition of peptide. 225 
Then, cells were plated at 2.5 × 10
4
 cells per 100 μL. The assay was finished by 226 
aspiration of wells. Cell adhesion was quantified by adding 1 mg/mL of MTT followed 227 
by 1 h incubation. DMSO (50 μL) was added to each well to dissolve formazan crystals 228 
and the absorbance at 570 nm, with a reference wavelength at 630 nm (Muñoz-Moreno 229 
et al., 2013). 230 
2.9. Wound healing assay 231 
MDA-MB-468 and PC-3 cells were incubated in 24-well plates and a small wound area 232 
was performed in the confluent monolayer with a scraper. Cells were incubated in the 233 
absence (control) or presence of peptide LLPSY at concentrations of 62.91 μg/mL (in 234 
the case of PC-3 cells) and 97.56 μg/mL (in the case of MDA-MB-468 cells). Three 235 
representative fields of each wound were photographed by a Nikon Diaphot 300 236 
inverted microscopy at different times (0 and 24 h). Wound areas of samples were 237 
averaged and assigned a value of 100% at 0 h (Muñoz-Moreno et al., 2013). 238 
2.10. Cell cycle analysis 239 
PC-3 and MDA-MB-468 cells were grown in 6-well plates. After 24 h, the culture 240 
medium was removed and replaced with RPMI-1640 medium containing 10% FBS and 241 




































































cells were subjected to various treatments for 8 h. Then, cells were washed with PBS 243 
and detached with 0.25% trypsin/0.2% EDTA. After centrifugation at 500g for 5 min at 244 
4 ºC, the pellets were mixed with ice-cold ethanol (70%) and kept at 20 ºC for 30 min. 245 
After ethanol removing by centrifugation, the pellets were washed with PBS and 246 
centrifuged again. The supernatants were discarded and the pellets suspended in PBS, 247 
0.2 mg/mL RNase A and 20 mg/mL PI before flow cytometry analysis. Results obtained 248 
were analyzed with the Cyflogic v 1.2.1 program (Turku, Finland) (Muñoz-Moreno, 249 
Bajo, Prieto & Carmena, 2017). 250 
2.11 Data analysis 251 
Data were subjected to one-way ANOVA and differences were determined by 252 
Bonferroni’s multiple comparison test with GraphPad Prism software. Each experiment 253 
was repeated at least three times. Data are the means of individual experiments and 254 





































































3. RESULTS AND DISCUSSION 257 
A previous work, reported by our research team, revealed that olive seeds and fruit 258 
seeds are sustainable and cheap sources of peptides with antihypertensive activity and 259 
that most active ones were always concentrated in the fraction, obtained by 260 
ultrafiltration, that contained peptides with MW below 3 kDa (Esteve et al., 2015, 261 
Vásquez-Villanueva et al., 2015; González-García, Marina, & García, 2015). In the 262 
present work, this fraction (OS-3kDa) has been further studied in order to obtain a 263 
deeper knowledge on peptides showing high bioactivity. For that purpose, OS-3kDa 264 
ultrafiltration fraction was next fractionated by semipreparative RP-HPLC and peptides 265 
in most active fractions were characterized.  266 
3.1. ACE-inhibitory capacity of fractions obtained from OS-3kDa by semipreparative 267 
RP-HPLC  268 
Figure 1 depicts the chromatogram yielded by the OS-3kDa and the fractions collected. 269 
Moreover, Figure 1 also shows the percentage of ACE inhibition reached by the 8 270 
collected fractions. Fractions F1, F3, F4, and F5 showed the highest percentage of ACE-271 
inhibition (65-74%) while fractions F2 and F8 were the less active. Additionally, the 272 
IC50 was measured for those fractions exceeding 50% of ACE-inhibition (F1, F3, F4 273 
and F5) and results are shown in Figure 1. Fraction F5 showed the lowest IC50 value 274 
(3.6 ± 0.9 µg/mL). This value was even lower than the obtained for the whole OS-3kDa 275 
(29.6 ± 0.5 µg/mL), which means that this fraction was, at least, eight times more active 276 
than OS-3kDa. This is a high antihypertensive activity in comparison with purified 277 
peptides from red algae, where the most active fractions reached an IC50 of 57.2 ± 5.0 278 
µg/mL (Wu et al., 2017) or even fractions derived from caprine kefir with IC50 values 279 
higher than 21 µg/mL (Quirós, Hernández-Ledesma, Ramos, Amigo, & Recio, 2005). 280 




































































observed in soybean (VLIVP (IC50 = 1.69 μM)) (Puchalska, García & Marina, 2014), 282 
corn (LQP (IC50 = 2.0 μM), LSP (IC50 = 1.7 μM), and LRP (IC50 = 0.29 μM), and milk 283 
(VPP (IC50 = 9.13 μM) and IPP (IC50 = 5.15 μM)) (Puchalska, Marina & García, 2012) 284 
could be obtained from the F5 olive seed fraction. All IC50 values were quite higher 285 
than the ACE-inhibitory drug exerted by Captopril
®
, which was used as positive control 286 
in our experiments. Indeed, Captopril reached 100% of ACE-inhibition and showed an 287 
IC50 = 5.0 ng/mL. In order to identify peptides with high bioactivity, F3, F4 and F5 288 
fractions were next analyzed by HPLC-MS/MS.  289 
 290 
3.2. Identification of peptides in fraction F5 by RP-HPLC- and HILIC-Q-ToF-MS  291 
Amino acid sequencing of peptides in fractions F3, F4, and F5, that exerted the lowest 292 
IC50, was carried out by RP-HPLC-ESI-Q-ToF. Table 1 summarizes the peptides 293 
identified by MS/MS for these 3 fractions. Antihypertensive peptides are usually short 294 
size, present a significant amount of hydrophobic amino acids (A, F, I, L, M, P, W and 295 
V), and also they contain aromatic amino acids (F, H, Y) in the first three C-terminal 296 
positions (Amado, Vázquez, González, Esteban-Fernández, Carrera, & Pineiro, 2014; 297 
Ghassem, Babji, Said, Mohmoodani, & Aeihara, 2014; Balti, Bougatef, Sila, 298 
Guillochon, Dhulster, & Nedjar-Arroume, 2015). Sixteen and fifteen peptides could be 299 
identified in F3 and F4 fractions, respectively. All of them showed less than 10 amino 300 
acids and MW below 1 kDa. The contribution of hydrophobic and aromatic amino acids 301 
was 54%, in the fraction F3, and 57%, in the fraction F4. A further analysis of peptides 302 
was carried out in fraction F5 due to its higher antihypertensive activity and the lower 303 
number of identified peptides. In addition to RP-HPLC, fraction F5 was also separated 304 
by hydrophilic interaction liquid chromatography (HILIC) that enabled a better 305 




































































antihypertensive peptides, presenting 4-6 amino acids and MW below 1 kDa. When 307 
separation was carried out by RP-HPLC, 7 peptides were identified and the contribution 308 
of hydrophobic and aromatic amino acids residues was around 84%, much higher than 309 
in the case of F3 and F4 fractions. When using HILIC, 4 peptides were identified and, 310 
unlike those peptides observed by RP-HPLC, a lower amount of hydrophobic and 311 
aromatic amino acids (around 76%) was observed within sequences. The hydrophobic 312 
and aromatic amino acid content in F5 was higher than the content in F3 and F4, that 313 
could explain its high antihypertensive activity. Additionally, MS/MS fragmentation of 314 
peptide LLPSY, identified by both chromatographic modes is shown in Figure 2. This 315 
peptide was also observed in the most antihypertensive fraction obtained from an 316 
Arbequina variety olive seed by Esteve et al. (2015).  317 
3.3. Cytotoxicity of peptides in fraction F5 318 
Cytotoxicity of peptides in fraction F5 was evaluated by the MTT assay using two 319 
different cell lines, one healthy line (HK-2 cells) and one cancer line (HeLa cells). 320 
Fraction F5 did not show cytotoxic effects in any cell line, exerting cell viability values 321 
higher than 80%, even at higher concentrations than the IC50 (data not shown).  322 
3.4. Characterization of the synthesized peptide LLPSY 323 
Within peptides identified in fraction F5, peptide LLPSY was selected for its synthesis 324 
and study since it was the only one that had been previously identified as 325 
antihypertensive peptide in the olive seed (Esteve et al., 2015). The percentage of ACE-326 
inhibition of peptide LLPSY was 95.2% and the IC50 was 23.6 ± 0.3 µg/mL (39.9 ± 0.5 327 
µM). Surprisingly, this value was higher than the calculated previously for the whole 328 
fraction F5 (3.6 ± 0.9 µg/mL). Furthermore, the resistance of LLPSY to gastrointestinal 329 




































































inhibition to 11.6%. Similar behavior was observed in some synthesized peptides from 331 
caprine kefir peptides. In both cases, this behavior could be justified by the partial or 332 
total hydrolysis of the peptide, due to gastrointestinal enzymes, and to the lack of 333 
activity of resulting peptides or amino acids (Quirós et al., 2005). 334 
In parallel, cytotoxicity of peptide LLPSY was evaluated using several cell lines, one 335 
healthy line (HK-2 cells) and three cancer lines (HeLa, PC-3, and MDA-MB-468). 336 
Unlike the whole F5 fraction, LLPSY caused a different cytotoxicity in the cell lines 337 
(see Figure 3). It did not show cytotoxic effects at any concentration in healthy HK-2 338 
cells and in cancer HeLa cells. However, LLPSY peptide treatment showed a strong 339 
anti-proliferative effect dose-dependent manner in PC-3 and MDA-MB-468 cancer cells 340 
after 24 h (Figure 3C and 3D). Indeed, both cancer cell lines showed IC50 values lower 341 
than 100 µg/mL (IC50 = 86.1 ± 2.6 μg/mL for the prostate cancer PC-3 cells and 97.6 ± 342 
1.9 μg/mL for the breast cancer MDA-MB-468 cells). In the same direction, the 343 
antiproliferative effects of lunasin peptide and common bean have been defined in colon 344 
and breast cancer cells (Dia, & Gonzalez de Mejia, 2011; Chan, Zhang, & Ng, 2013, 345 
Wu, Zhang, Wang, & Ng, 2011). Taking into account these results, and that LLPSY 346 
presents common characteristics with other antitumor peptides (Hernández-Ledesma et 347 
al., 2017, Kim et al., 2013; Chan et al., 2013; Wu et al., 2011), further studies to assess 348 
anti-carcinogenic activity of this peptide were next carried out.  349 
3.5. Effect of peptide LLPSY on several tumoral processes 350 
Additional studies to evaluate the capability of peptides to modify the adhesion and 351 
migration processes of cancer cells in presence of peptide LLPSY and its capacity to 352 




































































Cell adhesion is an essential aspect of cell survival for metastatic tumor cells. When cell 354 
adhesion is disrupted, cancer cells are able to migrate to other healthy tissues and could 355 
lead to metastatic processes (Fernández-Martínez, Bajo, Sánchez-Chapado, Prieto, & 356 
Carmena, 2009). Cell adhesion assay was carried out by treating PC-3 and MDA-MB-357 
468 cells with LLPSY peptide at concentrations corresponding to the IC50 (86.1 μg/mL 358 
for PC-3 and 97.6 μg/mL for MDA-MB-468). Figure 4A shows that the treatment with 359 
LLPSY resulted in increasing cellular adhesion in both cell lines, observing a higher 360 
effect on breast cancer cells (37% increase) than in prostatic cancer cells (21% 361 
increase).  362 
Furthermore, in order to evaluate whether LLPSY could modify the capability of cancer 363 
cells to migrate to other tissues, the wound-healing assay was employed. For that 364 
purpose, after performing the wound on the cells monolayer, it was treated with LLPSY 365 
peptide at concentrations corresponding to the IC50 (86.1 μg/mL for PC-3 and 97.6 366 
μg/mL for MDA-MB-468). Figure 4B shows that the presence of peptide significantly 367 
retarded the close of the wound as compared to untreated cancer cells (controls) after 24 368 
h of treatment. Lowering migration capability of cells in presence of peptide was more 369 
significant on breast cancer cells (63%) than on prostate cancer cells (49%). In this 370 
regard, other peptides derived from food, like those present in soybean, have 371 
demonstrated inhibitory effect on cancer cell migration (Lima, Oliveira, Saúde, Mota, & 372 
Ferreira, 2017).   373 
The cell cycle consists of several well controlled phases or stages. Briefly, in G1 phase, 374 
the cell grows in size and synthesizes all it needs to duplicate DNA in S phase. In G2 375 
phase, cell growths rapidly and prepares for mitosis in M phase. In M phase, chromatids 376 
are separated. After daughter cells are separated in cytokinesis, they can enter again to 377 




































































process. In order to find out the reasons involved on the anti-proliferative effects in 379 
presence of peptide LLPSY on PC-3 and MDA-MB-468 cells, the cell cycle analysis 380 
was carried out. Figure 5 shows that the treatment of cells with peptide resulted in an 381 
increase of the number of cells in sub G0 phase and a decrease of the number of cells in 382 
G2/M phase. These results could indicate that peptide LLPSY arrests cell cycle on S 383 
phase. Similar results were observed for other peptides such as lunasin from soybean 384 
that showed capacity to arrest cell cycle in S phase on breast cancer cells (MDA-MB-385 
231) (Hsieh, Hernández-Ledesma, & de Lumen, 2010) and at G2/M phase on metastatic 386 
colon cell line KM12L4 (Dia et al., 2011) or peony polysaccharides that arrested cervix 387 
cancer cell cycle at S phase (Zhang, Shi, Thakhur, Hu, Zhang, & Wei, 2017).  388 
Take all together, the results suggest that LLPSY peptide shows antiproliferative and 389 
antimetastatic effects on prostate and breast cancer cells. However, further studies are 390 




































































4. CONCLUSIONS 392 
Fraction containing peptides with MW less than 3 kDa from an olive seed hydrolysate 393 
has demonstrated high antihypertensive capacity (IC50 = 29.6 ± 0.5 µg/mL). A further 394 
fractionation by semipreparative RP-HPLC enabled to concentrate highly 395 
antihypertensive peptides in a subfraction exerting an IC50 = 3.6 ± 0.9 µg/mL. The 396 
analysis of this fraction by LC-MS/MS required the use of reverse phase and 397 
hydrophilic liquid interaction chromatography for the comprehensive identification of 398 
peptides. Ten peptides with common characteristic with antihypertensive peptides were 399 
identified. This fraction did not show cytotoxic effects on HeLa and HK-2 cell lines. 400 
Nevertheless, synthetic peptide LLPSY, identified in previous fraction, showed a huge 401 
anti-proliferative effect on aggressive stages of prostate cancer cells (PC-3) and breast 402 
cancer cells (MDA-MB-468). Further studies to asses this effect by the evaluation of the 403 
capacity of LLPSY peptide to modify cell adhesion, migration, and cell cycle processes 404 
enabled to confirm the potential antitumor character of this peptide from the olive seed. 405 
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FIGURE CAPTIONS  549 
Figure 1. Chromatogram obtained by semipreparative RP-HPLC of peptides with MW 550 
below 3 kDa from the olive seed hydrolysate, ACE-inhibitory capacity of fractions (F1-551 
F8) expressed as % of ACE- inhibition, and IC50 values of most active fractions.  552 
Figure 2. Fragmentation spectrum of peptide LLPSY in fraction F5 of the olive seed 553 
hydrolysate. 554 
Figure 3. Cell viability of human cell lines HK-2 (A), HeLa (B), PC-3 (C), and MDA-555 
MB-468 (D) after treating with peptide LLPSY. The results are expressed as percentage 556 
of control value. Data are mean ± SEM of at least three independent experiments; ***p 557 
< 0.001. 558 
Figure 4. (A) Cell adhesion and (B) cell migration capacity of PC-3 prostate and MDA-559 
MB-468 breast cancer cells in presence or absence of synthesized peptide LLPSY at 0 560 
min () and at 80 min (). (B) The results are expressed as percentage of control 561 
value. Data are mean ± SEM of at least three independent experiments; **p < 0.01; 562 
***p < 0.001. 563 
Figure 5. Analysis of cell cycle in prostate cancer PC-3 cells (A) and in breast cancer 564 
MDA-MB-468 cells (B) after treatment with 87.1 μg/mL and 97.56 μg/mL of peptide 565 
LLSPY, respectively. The results are shown as % of cells in each phase of the cycle 566 
compared to untreated control. Data are mean ± SEM of at least three independent 567 
experiments; *p < 0.05; **p < 0.01. 568 
Table 1. Sequence, ALC, mass, retention time, and mass accuracy obtained in the 
identification of peptides in fractions F3, F4, and F5 collected by semipreparative RP-
HPLC from an olive seed hydrolysate by RP-HPLC- and HILIC-ESI-Q-ToF (in the case 
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